Dance clubbing on MDMA and during abstinence from ecstasy/MDMA: Prospective neuroendocrine and psychobiological changes

Neuropsychobiology

Volumn 57, Issue 4, 2008, Pages 165-180

  Parrott, A C ^a   Lock, J ^a   Conner, A C ^c   Kissling, C ^b   Thome, J ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA); Cortisol; Ecstasy; Energy; Neuroendocrine; Serotonin; Stress; Temperature; Testosterone

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; HYDROCORTISONE;

ADULT; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DANCING; DRUG DEPENDENCE; DRUG WITHDRAWAL; ENVIRONMENTAL TEMPERATURE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SALIVA ANALYSIS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BODY TEMPERATURE REGULATION; CENTRAL NERVOUS SYSTEM STIMULANTS; DANCING; ENERGY METABOLISM; FEMALE; HALLUCINOGENS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PHYSICAL EXERTION; PROSPECTIVE STUDIES; REFERENCE VALUES; SALIVA; SELF ADMINISTRATION; SELF ASSESSMENT (PSYCHOLOGY); STREET DRUGS; TESTOSTERONE; YOUNG ADULT;

EID: 47649112938     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000147470     Document Type: Article

References (85)

1. Bedi G, Redman J: Recreational Ecstasy use: acute effects potentiated by ambient conditions? Neuropsychobiology 2006;53:113.
2. Dumont GJ, Verkes RJ: A review of acute effects of 3,4- methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 2006;20:176-187.
3. Parrott AC: Human research on MDMA (3,4-methylenedioxy-methamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 2000;42:17-24.
4. Parrott AC: MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004b;50:329-335.
5. Schifano F: Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000;42:25-33.
6. Zhou JF, Chen P, Zhou YH, Zhang L, Chen HH: 3,4- methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage. Free Radic Res 2003;37:491-497.
7. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Pharmacol Rev 2003;55:463-508.
8. Green A, O'Shea E, Colado I: A review of the mechanisms involved in the acute MDMA(Ecstasy)-induced hyperthermic response. Eur J Pharmacol 2004b;500:3-13.
9. Morton J: Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005;5:79-86.
10. Carlezon WA Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, Duman RS, Neve RL, Nestler EJ: Regulation of cocaine reward by CREB. Science 1998;282:2272-2275.
11. Parrott AC: MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 2006;20:147-163.
12. Tancer ME, Johanson CE: The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2007;189:565-573.
13. Cohen RS: The Love Drug. Marching to the Beat of Ecstasy. New York, Haworth Medical Press, 1998.
14. Parrott AC: Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research. Hum Psychopharmacol 2001;16:557-577.
15. Parrott AC: Is Ecstasy MDMA? A review of the proportion of Ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 2004a;173:234-241.
16. Curran HV, Travill RA: Mood and cognitive effects of 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy'): weekend 'high' followed by mid-week 'low'. Addiction 1997;92:821-831.
17. Curran VH, Rees H, Hoare T, Hoshi R, Bond A: Empathy and aggression: two faces of Ecstasy? A study of interpretative cognitive bias and mood change in Ecstasy users. Psychopharmacology 2004;173:425-433.
18. Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 1998;139:261-268.
19. Hoshi R, Pratt H, Mehta S, Bond AJ, Curran HV: An investigation into the sub-acute effects of Ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences? J Psychopharmacol 2004;20:291-301.
20. Jones K, Callen F, Blagrove M, Parrott AC: Self-rated sleep 7 days following recreational Ecstasy/MDMA use. J Psychopharmacol 2007;21:a28.
21. McCann UD, Eligulashvili V, Ricaurte GA: 3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000;42:11-16.
22. Turner JJD, Nicolas L, Parrott AC: Reduced calorie intake in the week following weekend MDMA (Ecstasy) use. J Psychopharmacol 1998;12:a43.
23. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT: Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002;162:396-405.
24. De la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, Cami J: Pharmacology of MDMA in humans. Ann NY Acad Sci 2000;914:225-237.
25. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J: Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 2004;173:364-375.
26. Mas M, Farré M, De La Torre R, Roset PN, Ortuño J, Segura J, Camí J: Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999;290:136-145.
27. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Segura J, de la Torre R: Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 1999;65:309-316.
28. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN, Ortuno J, Pujadas M, Bacosi A, Menoyo E, Segura J, de la Torre R: Effects of repeated doses of MDMA ('Ecstasy') on cell-mediated immune response in humans. Life Sci 2001;69:2931-2941.
29. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari C, Brambilla F: Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('Ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res 2003;120:115-124.
30. Parrott AC, Margetson J, Thome JC: Cigarettes, Ecstasy and the inverse of pleasure: nicotine abstinence effects in recreational Ecstasy/MDMA users. J Psychopharmacol 2005a;19:a27.
31. Parrott AC: Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71:837-844.
32. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB: Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum Psychopharmacol 2006;21:285-298.
33. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999;55:105-115.
34. Tossman P, Boldt S, Tensil MD: The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 2001;7:2-23.
35. Winstock AR, Griffiths P, Stewart D: Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001;64:9-17.
36. Suy K, Gijsenbergh F, Baute L: Emergency medical assistance during a mass gathering. Eur J Emerg Med 1999;6:249-254.
37. Freedman FR, Johanson C, Tancer ME: Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2005;183:248-256.
38. Tancer ME, Johanson CE, Freedman RR: MDMA elevates core temperature in warm and cold conditions in man. Abstract Annu Conf Coll Probl Drug Depend, Florida, June 2003, p 169.
39. Grob CS, Poland RE, Chang L, Ernst T: Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 1996;73:103-107.
40. Vollenweider FX, Gamma A, Liechti M, Huber T: Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA naïve healthy volunteers. Neuropsychopharmacology 1998;19:241-251.
41. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM: Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 2006;31:424-430.
42. Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A: Preliminary evidence of the cardiovascular effects of polysubstance misuse in night clubs. J Psychopharmacol 2005;19:67-70.
43. Parrott AC, Young L: Increased body temperature in recreational Ecstasy/MDMA users out clubbing and dancing. J Psychopharmacol 2005;19:a26.
44. Parrott AC, Milani R, Parmar R, Turner JJD: Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001;159:77-82.
45. Milani RM, Parrott AC, Schifano F, Turner JJD: Patterns of cannabis use in Ecstasy polydrug users: moderate cannabis use may compensate for self-rate aggression and somatic symptoms. Hum Psychopharmacol 2005;20:1-13.
46. Rodgers J, Buchanan T, Pearson C, Parrott AC, Ling J, Heffernan TM, Scholey AB: Differential experiences of the psychobiological sequelae of Ecstasy use: quantitative and qualitative data from an Internet study. J Psychopharmacol 2006;20:437-446.
47. Rudolph DL, McAuley E: Self-efficacy and salivary cortisol responses to acute exercise in physically active and less active adults. J Sport Exerc Psychol 1995;17:206-213.
48. Davis H, Gass G, Bassett J: Serum cortisol response to incremental work in experienced and naïve subjects. Psychosom Med 1981;43:127-132.
49. Kirwan J, Costill D, Flynn M, Mitchell J, Fink W, Neufer P, Houmard J: Physiological responses to successive days of intense training in competitive swimmers. Med Sci Sports Exerc 1988;20:255-259.
50. Lovallo WR: Stress and Health: Biological and Psychological Interactions. Thousand Oaks, Sage, 1997.
51. Jackson B, Reed A: Another abusable amphetamine. JAMA 1970;211:830.
52. Buffum J, Moser C: MDMA and human sexual function. J Psychoact Drugs 1986;18:355-359.
53. Laloup M, Tilman G, Maes V, De Boeck G, Wallemacq P, Ramaekers J, Samyn N: Validation of an ELISA-based screening assay for the detection of amphetamine, MDMA and MDA in blood and oral fluid. Forensic Sci Int 2005;153:29-37.
54. Davison D, Parrott AC: Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 1997;12:91-97.
55. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI: Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxy- methamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 2004a;173:264-269.
56. Greer G, Tolbert R: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-327.
57. Parrott AC: The psychotherapeutic potential of MDMA (3,4- methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 2007;191:181-193.
58. Curran V: Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 2000;42:34-41.
59. Verheyden SL, Hadfield J, Calin T, Curran HV: Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, 'Ecstasy') on mood: evidence of gender differences. Psychopharmacology 2002;161:23-31.
60. Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J: Ecstasy-attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002;17:309-312.
61. Rendell PG, Gray TJ, Henry JD, Tolan A: Prospective memory impairment in 'Ecstasy' (MDMA) users. Psychopharmacology 2007;194:497-504.
62. Bolla KI, McCann UD, Ricaurte GA: Memory impairment in abstinent MDMA ('Ecstasy') users. Neurology 1998;51:1532-1537.
63. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ: Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('Ecstasy') polydrug users. Psychopharmacology 2002;162:203-214.
64. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992;18:331-341.
65. Morgan MJ: Memory deficits associated with recreational use of 'Ecstasy' (MDMA). Psychopharmacology 1999;141:30-36.
66. Reay JL, Hamilton C, Kennedy DO, Scholey AB: MDMA polydrug users show processspecific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol 2006;20:385-388.
67. Rodgers J: Cognitive performance amongst recreational users of 'Ecstasy'. Psychopharmacology 2000;151:19-24.
68. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H: Impaired cognitive performance in drug-free users of recreational Ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000;68:719-725.
69. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K: Cognitive performance in recreational users of MDMA or 'Ecstasy': evidence for memory deficits. J Psychopharmacol 1998;12:79-83.
70. Wareing M, Fisk JE, Murphy PN: Working memory deficits in current and previous users of MDMA ('Ecstasy'). Br J Psychol 2000;91:181-188.
71. Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Yurgelun-Todd D: Residual effects of illicit 3,4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004;75:135-147.
72. Fisk JE, Montgomery C, Wareing M, Murphy PN: Reasoning deficits in Ecstasy (MDMA) polydrug users. Psychopharmacology 2005;181:550-559.
73. Fox H, Parrott AC, Turner JJD: Ecstasy/MDMA-related cognitive deficits: a function of dosage rather than awareness of problems. J Psychopharmacol 2001;15:273-281.
74. Zakzanis KK, Young DA: Memory impairment in abstinent MDMA ('Ecstasy') users: a longitudinal investigation. Neurology 2001;56:966-969.
75. Zakzanis KK, Campbell Z: Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 2006;66:740-741.
76. Schifano F, Magni G: MDMA ('Ecstasy') abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry 1994;36:763-767.
77. Soar K, Parrott AC, Turner JJD: Persistent neuropsychological problems after seven years of abstinence from recreational Ecstasy (MDMA): a case study. Psychol Rep 2004;95:192-196.
78. Craig D, Parrott AC, Coomber J: Smoking cessation in women: effects of the menstrual cycle. Int J Addict 1992;27:697-706.
79. Mishra GD, Dobson AJ, Schofield MJ: Cigarette smoking, menstrual symptoms and miscarriage among young women. Aust NZ J Public Health 2000;24:413-420.
80. Darvesh AS, Gudelsky GA: Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT. Brain Res 2005;21:168-175.
81. Huether G, Zhou D, Rüther E: Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy') and its congeners. J Neural Transm 1997;104:771-794.
82. Parrott AC: Recreational Ecstasy use: acute effects potentiated by ambient conditions (author's reply). Neuropsychobiology 2006;53:113.
83. Yau JL, Noble J, Seckl JR: Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxymethamphetamine: role of corticosterone and serotonin. Neuroscience 1997;78:111-121.
84. Bergomi M, Rovesti S, Vivoli G: Biological response to noise and other physical stressors in places of entertainment. Public Health Rev 1991;19:263-275.
85. Parrott AC, Adnum L, Evans A, Kissling C, Thome J: Heavy Ecstasy/MDMA use and cool house parties: substantial cortisol release and increased body temperature. J Psychopharmacol 2007;21:a35.